Development of a Dual Drug-Loaded, Surfactant-Stabilized Contrast Agent Containing Oxygen.
dual drug loading
microbubbles
oxygen delivery
surfactant
theranostic agents
ultrasound contrast agent
ultrasound-triggered drug delivery
Journal
Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357
Informations de publication
Date de publication:
12 Apr 2022
12 Apr 2022
Historique:
received:
07
03
2022
revised:
01
04
2022
accepted:
07
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Co-delivery of cancer therapeutics improves efficacy and encourages synergy, but delivery faces challenges, including multidrug resistance and spatiotemporal distribution of therapeutics. To address these, we added paclitaxel to previously developed acoustically labile, oxygen-core, surfactant-stabilized microbubbles encapsulating lonidamine, with the aim of developing an agent containing both a therapeutic gas and two drugs acting in combination. Upon comparison of unloaded, single-loaded, and dual-loaded microbubbles, size (~1.7 µm) and yield (~2 × 10
Identifiants
pubmed: 35458319
pii: polym14081568
doi: 10.3390/polym14081568
pmc: PMC9027498
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB026881
Pays : United States
Organisme : National Institute of Health
ID : EB026881
Références
Chem Rev. 2017 Nov 22;117(22):13566-13638
pubmed: 29048884
Eur J Pharm Sci. 2013 May 13;49(2):175-86
pubmed: 23485439
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
J Natl Cancer Inst. 1981 Mar;66(3):497-9
pubmed: 6937706
Colloids Surf B Biointerfaces. 2021 Dec;208:112049
pubmed: 34454362
Methods Mol Biol. 2010;596:47-76
pubmed: 19949920
Chem Pharm Bull (Tokyo). 2020;68(7):603-612
pubmed: 32611997
Int J Pharm. 2015 Jan 15;478(1):361-367
pubmed: 25448552
Cancer Chemother Pharmacol. 1998;42(3):177-82
pubmed: 9685052
Cells. 2019 Dec 24;9(1):
pubmed: 31878360
Curr Mol Med. 2009 May;9(4):442-58
pubmed: 19519402
Biomaterials. 2020 May 3;251:120088
pubmed: 32388167
Cancers (Basel). 2020 Nov 11;12(11):
pubmed: 33187214
Theranostics. 2014 Jan 29;4(4):399-411
pubmed: 24578723
Drug Des Devel Ther. 2014 Feb 20;8:279-84
pubmed: 24591817
ACS Nano. 2018 Mar 27;12(3):2426-2439
pubmed: 29533606
Langmuir. 2019 Aug 6;35(31):10068-10078
pubmed: 30827115
Ultrasonics. 2006 Nov;44(4):360-7
pubmed: 16730047
Int J Toxicol. 2010 Jan-Feb;29(1):32-9
pubmed: 20008819
Medicine (Baltimore). 2019 Jul;98(27):e16167
pubmed: 31277121
J Pharm Sci. 1996 Feb;85(2):228-31
pubmed: 8683453
Br J Radiol. 2011 Oct;84(1006):903-18
pubmed: 21933980
Int J Pharm. 2011 Jul 29;414(1-2):161-70
pubmed: 21609756
Exp Mol Pathol. 1988 Dec;49(3):361-72
pubmed: 3197815
Cancer Res. 1994 Sep 15;54(18):4980-7
pubmed: 7915196
Mol Pharm. 2012 Aug 6;9(8):2302-13
pubmed: 22681126
Biomaterials. 2016 Oct;103:197-206
pubmed: 27388945
Biomaterials. 2015 Dec;73:284-95
pubmed: 26426537
Eur J Pharm Biopharm. 2018 Dec;133:285-308
pubmed: 30463794
Cancer Cell Int. 2011 Feb 14;11:3
pubmed: 21320311
Res Pharm Sci. 2020 Aug 28;15(4):312-322
pubmed: 33312209
Biomaterials. 2018 Jul;171:178-197
pubmed: 29698868
Biochim Biophys Acta. 2016 Dec;1866(2):151-162
pubmed: 27497601
Laryngoscope. 1995 Dec;105(12 Pt 1):1294-9
pubmed: 8523980
Wien Med Wochenschr. 2002;152(13-14):334-42
pubmed: 12168517
Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):88-96
pubmed: 29477294
Adv Drug Deliv Rev. 2016 Mar 1;98:3-18
pubmed: 26546465
Cancer. 1998 Sep 1;83(5):851-7
pubmed: 9731886
Methods Mol Biol. 2016;1395:1-18
pubmed: 26910065
J Control Release. 2015 Aug 28;212:30-40
pubmed: 26065734
Biomaterials. 2019 Feb;192:1-14
pubmed: 30415101
Sci Rep. 2021 Apr 26;11(1):8909
pubmed: 33903618
Pharmaceutics. 2021 Aug 28;13(9):
pubmed: 34575432
Cancers (Basel). 2018 Oct 10;10(10):
pubmed: 30308958
J Ultrasound Med. 2019 Dec;38(12):3221-3228
pubmed: 31124171